Co-primary endpoints were met , with demonstration of superiority for each secukinumab dose vs. placebo at week @ ( PASI @ : @ % , @ % and @ % for secukinumab @mg , @mg and placebo ; IGA mod @@/@ : @ % , @ % and @ % , respectively ; P < @ for all comparisons vs. placebo ) .